A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation

Transplantation

Volumn 63, Issue 1, 1997, Pages 33-38

  Vincenti, Flavio ^a   Lantz, Marianne ^b   Birnbaum, Jytte ^b   Garovoy, Marvin ^b   Mould, Diane ^b   Hakimi, John ^b   Nieforth, Keith ^b   Light, Susan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AZATHIOPRINE; CYCLOSPORIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2;

EID: 0031014538     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199701150-00007     Document Type: Article

References (25)

1. Smith KA. Interleukin-2: inception, impact and implications. Science 1988; 240: 1169.
2. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993; 11: 245.
3. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells: II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J Immunol 1981; 126: 1398.
4. Depper JM, Leonard WJ, Robb RJ, Waldmann TA, Greene WC. Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol 1983; 131: 690.
5. Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA, Greene WC. A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor: partial characterization of the receptor. Nature 1982; 300: 267.
6. Kupiec-Weglinski JW, Diamantstein T, Tilney NL. Interleukin 2 receptor-targeted therapy-rationale and applications in organ transplantation. Transplantation 1988; 46: 785.
7. Kirkman RL, Barrett LV, Galuton GN, et al. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs allograft survival in mice. J Exp Med 1985; 162: 358.
8. Reed MH, Shapiro ME, Strom TB, et al. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation 1989; 47: 55.
9. Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
10. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107.
11. van Gelder T, Zietse R, Mulder AH, et al. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 1995; 60: 248.
12. Wiesel M, Carl S, Pomer S, Waldherr R, Daniel V, Staehler G. Effect of the anti-IL2 receptor monoclonal antibody BT-563 in treatment of acute interstitial renal rejection [Abstract]. Presented at the American Urological Association annual meeting, Las Vegas, Nevada, April 26-30, 1995.
13. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989; 86: 10029.
14. Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990; 50: 1495.
15. Hakimi J, Chizzonite R, Luke D, et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol 1991; 147: 1352.
16. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320.
17. Brown PS, Parenteau GL, Dirbas FM, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 1991; 88: 2663.
18. Fayer BE, Soui PP, Binger MH, Mould DR, Satoh H. Determination of humanized anti-Tac in human serum by a sandwich enzyme-linked immunosorbent assay. J Immunol Methods 1995; 186(1): 47.
19. Beal S, Scheiner LB. NONMEM user's guide. San Francisco: NONMEM Project Group, University of California at San Francisco, CA, 1992.
20. Trang JM, LoBuglio AF, Wheeler RH, et al. Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients. Pharm Res 1990; 7: 587.
21. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics an immune response. Proc Natl Acad Sci USA 1989; 86: 4220.
22. Vincenti F, Danovitch G, Neylan JF, Steiner RW, Everson MP, Gaston RS. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3 - a randomized, double-blind placebo-controlled study. Transplantation 1996; 61: 573.
23. Stock PG, Lantz M, Light S, Vincenti F. In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients. Transplant Proc 1996; 88: 925.
24. Hale G, Dyer MJS, Clarke MR, et al. Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody campath-1H. Lancet 1988; 2: 1394.
25. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748.